

Please amend the claims as follows:

A¹ 40.(amended) The composition of claim[s] ~~31~~ 31-38], wherein the agent is an antibody.

A² 42.(amended) A composition of matter comprising
a conjugate of the agent of claims ~~31~~ 31-41] and 40 and a therapeutic or diagnostic agent.

A³ 49.(amended) A pharmaceutical composition comprising
an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, or an
HLA binding fragment thereof and
a pharmaceutically acceptable carrier.

A⁴ 58.(amended) The pharmaceutical composition of claim[s] 49[-57], further comprising an
adjuvant.

A⁵ 71.(amended) An expression vector comprising an isolated nucleic acid molecule of claim[s]
59[, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 or 70] operably linked to a promoter.

A⁶ 74.(amended) A host cell transformed or transfected with an expression vector of claims 71,
[72,] or 73.

75.(amended) A host cell transformed or transfected with an expression vector of claim 71 [or
claim 72] and further comprising a nucleic acid encoding HLA.

76.(amended) An isolated polypeptide encoded by the isolated nucleic acid molecule of claim[s]
59[, 60, 61, 62, 63, 64, 65, or 66].

A⁷ 102.(amended) A method for treating a condition characterized by expression in a subject of
abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic
acid molecule, comprising


AM
can
administering to a subject a pharmaceutical composition of any one of claims 18, [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,] 44[, 45, 46, 47, 48,] and 49[, 50, 51, 52, 53, 54, 55, 56, 47, and 58] in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.

112. (amended) A composition of matter useful in stimulating an immune response to a plurality of [a] proteins encoded by nucleic acid molecules that are NA Group 1 molecules, comprising a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

Remarks

002050-62625400
Please enter this amendment prior to calculation of the fees. The amendments to the specification were made to correct typographical errors and reduce claims. Support for the amendment to claim 49 can be found in the claims as filed. No new matter has been added.

Respectfully submitted,


John R. Van Amsterdam, Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Docket No.: L0461/7078
Date: January 14, 2000
X01/17/00